Ocular Therapeutix will unveil topline results from SOL-1, its phase 3 superiority trial of AXPAXLI (OTX-TKI) in wet age-related macular degeneration, via a webcast on February 17, with a full data readout slated for the Macula Society meeting later in the month. AXPAXLI is an intravitreal, bioresorbable hydrogel formulation of the tyrosine kinase inhibitor axitinib using the company’s Elutyx delivery platform. Beyond wet AMD, the asset is being studied in diabetic retinal disease, including non-proliferative diabetic retinopathy, positioning Ocular to pursue a multi-indication durability strategy in a retina market defined by treatment burden and clinic capacity constraints.
The strategic question is whether a TKI-based, sustained-release hydrogel can convincingly outperform standard anti-VEGF regimens on vision and durability to reset the competitive baseline. If SOL-1 truly demonstrates superiority rather than non-inferiority, the implications extend well beyond another long-acting option. It would challenge the dominance of incumbent biologics and next-generation high-dose antibodies, and could reframe payer and guideline thinking around first-line therapy in a category where marginal efficacy gains have historically played second fiddle to dosing interval.
Why this matters now is simple: the wet AMD market is mature but still dissatisfied. Patients and caregivers remain fatigued by frequent injections and real-world undertreatment continues to erode outcomes compared with trial settings. Retina practices face mounting throughput pressure and staffing shortages, even as procedure-based revenue tied to injection frequency complicates incentives. Payers are intensifying scrutiny under Medicare Part B as biosimilars expand and site-of-service shifts accelerate. A therapy that demonstrably extends intervals with equal or better vision gains could unlock cost offsets in administration and visits, but it will need to overcome entrenched step edits and buy-and-bill dynamics that favor familiar agents. Clear safety, a predictable retreatment algorithm, and straightforward office operationalization will be essential to drive adoption.
The readout also intersects with broader industry currents reshaping retina. The durability race spans multiple modalities: high-dose antibodies, refillable reservoirs, suprachoroidal delivery, gene therapy, and small-molecule TKIs in sustained release. Several high-profile long-acting approaches have stumbled at phase 3, reminding the market that durability without uncompromised efficacy and safety is a high bar. Competitive pressure is intensifying from other TKI depots and device-enabled delivery, while gene therapy contenders aim for functional one-and-done paradigms. Against this backdrop, positive, superiority-level data could make Ocular a prime target for business development by ophthalmology leaders looking to diversify beyond anti-VEGF biologics and defend share as biosimilar erosion and pricing pressure build.
Commercial and Medical Affairs leaders should watch three details in the topline: dosing interval and retreatment criteria versus standard practice, the magnitude and consistency of vision and anatomic outcomes across patient subgroups, and the safety profile specific to intravitreal TKI exposure and hydrogel residence. These will dictate how aggressively payers can be engaged on access, how KOLs recalibrate treatment algorithms, and how quickly real-world evidence programs should be mobilized to validate clinic flow and adherence benefits. If SOL-1 clears the superiority bar with clean safety, AXPAXLI could force a reconsideration of first-line choices in wet AMD and set up a broader push into diabetic retinal disease. The next question is whether Ocular moves to scale alone or becomes a cornerstone in a larger player’s retina durability platform before competitors close the gap.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
